Trial Profile

A phase 2 study of HMPL-689 in patients with relapsed/refractory non-Hodgkin's lymphoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amdizalisib (Primary)
Indications Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use
Sponsors HUTCHMED

Most Recent Events

03 Mar 2022 According to a HUTCHMED media release, the company plans to initiate Phase II studies with potential for registration intent in China in additional relapsed/refractory non-Hodgkin's lymphoma indications in the second half of 2022.
04 Aug 2021 New trial record
28 Jul 2021 According to a HUTCHMED media release, the company expects to initiate this study in the late 2021 or early 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com